{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T04:38:02Z","timestamp":1720413482209},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40644-017-0112-x","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:12:54Z","timestamp":1488845574000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors"],"prefix":"10.1186","volume":"17","author":[{"given":"Sabrina","family":"Segreto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Fonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"112_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2008.01.014","volume":"60","author":"R Srirajaskanthan","year":"2008","unstructured":"Srirajaskanthan R, Toubanakis C, Dusmet M, Caplin ME. A review of thymic tumours. Lung Cancer. 2008;60:4\u201313.","journal-title":"Lung Cancer"},{"key":"112_CR2","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/j.crad.2014.01.005","volume":"69","author":"AM Priola","year":"2014","unstructured":"Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol. 2014;69:e230\u201345.","journal-title":"Clin Radiol"},{"key":"112_CR3","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","volume":"5","author":"A Masaoka","year":"2010","unstructured":"Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5:S304\u201312.","journal-title":"J Thorac Oncol"},{"key":"112_CR4","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6:S1710\u20136.","journal-title":"J Thorac Oncol"},{"key":"112_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2005.05.009","volume":"50","author":"O Rena","year":"2005","unstructured":"Rena O, Papalia E, Maggi G, Oliaro A, Ruffini E, Filosso P, et al. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer. 2005;50:59\u201366.","journal-title":"Lung Cancer"},{"key":"112_CR6","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","volume":"22","author":"P Strobel","year":"2004","unstructured":"Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22:1501\u20139.","journal-title":"J Clin Oncol"},{"key":"112_CR7","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1148\/rg.317115505","volume":"31","author":"MF Benveniste","year":"2011","unstructured":"Benveniste MF, Rosado-de-Christenson ML, Sabloff BS, Moran CA, Swisher SG, Marom EM. Role of imaging in the diagnosis, staging, and treatment of thymoma. Radiographics. 2011;31:1847\u201361. discussion 61-3.","journal-title":"Radiographics"},{"issue":"Suppl 5","key":"112_CR8","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v40\u201355.","journal-title":"Ann Oncol"},{"key":"112_CR9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","volume":"4","author":"CB Falkson","year":"2009","unstructured":"Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009;4:911\u20139.","journal-title":"J Thorac Oncol"},{"key":"112_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","volume":"4","author":"N Girard","year":"2009","unstructured":"Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J Thorac Oncol. 2009;4:119\u201326.","journal-title":"J Thorac Oncol"},{"key":"112_CR11","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","volume":"91","author":"PJ Loehrer Sr","year":"2001","unstructured":"Loehrer Sr PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas Jr CR, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010\u20135.","journal-title":"Cancer"},{"key":"112_CR12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29:2060\u20135.","journal-title":"J Clin Oncol"},{"key":"112_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","volume":"26","author":"F Hirai","year":"2015","unstructured":"Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26:363\u20138.","journal-title":"Ann Oncol"},{"key":"112_CR14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","volume":"21","author":"G Palmieri","year":"2010","unstructured":"Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol. 2010;21:1168\u201372.","journal-title":"Ann Oncol"},{"key":"112_CR15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/JTO.0b013e31821c4203","volume":"6","author":"EM Marom","year":"2011","unstructured":"Marom EM, Milito MA, Moran CA, Liu P, Correa AM, Kim ES, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol. 2011;6:1274\u201381.","journal-title":"J Thorac Oncol"},{"key":"112_CR16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ejcts\/ezu475","volume":"48","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Chen H, Shi J, Fan L, Hu D, Zhao H. The correlation of morphological features of chest computed tomographic scans with clinical characteristics of thymoma. Eur J Cardiothorac Surg. 2015;48:698\u2013704.","journal-title":"Eur J Cardiothorac Surg"},{"key":"112_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejrad.2007.10.002","volume":"69","author":"N Tomiyama","year":"2009","unstructured":"Tomiyama N, Honda O, Tsubamoto M, Inoue A, Sumikawa H, Kuriyama K, et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol. 2009;69:280\u20138.","journal-title":"Eur J Radiol"},{"key":"112_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/RTI.0b013e31828609a0","volume":"28","author":"EM Marom","year":"2013","unstructured":"Marom EM. Advances in thymoma imaging. J Thorac Imaging. 2013;28:69\u201380. quiz 1-3.","journal-title":"J Thorac Imaging"},{"key":"112_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.acra.2012.08.002","volume":"20","author":"YJ Qu","year":"2013","unstructured":"Qu YJ, Liu GB, Shi HS, Liao MY, Yang GF, Tian ZX. Preoperative CT findings of thymoma are correlated with postoperative Masaoka clinical stage. Acad Radiol. 2013;20:66\u201372.","journal-title":"Acad Radiol"},{"key":"112_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"112_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"112_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/RLU.0b013e318286bd84","volume":"38","author":"S Luca De","year":"2013","unstructured":"De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, et al. Combined imaging with 18F-FDG-PET\/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors. Clin Nucl Med. 2013;38:354\u20138.","journal-title":"Clin Nucl Med"},{"key":"112_CR23","first-page":"1628","volume":"47","author":"YM Sung","year":"2006","unstructured":"Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET\/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628\u201334.","journal-title":"J Nucl Med"},{"key":"112_CR24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.lungcan.2008.01.003","volume":"61","author":"M Endo","year":"2008","unstructured":"Endo M, Nakagawa K, Ohde Y, Okumura T, Kondo H, Igawa S, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61:350\u20135.","journal-title":"Lung Cancer"},{"key":"112_CR25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejrad.2010.08.010","volume":"81","author":"M Nakajo","year":"2012","unstructured":"Nakajo M, Kajiya Y, Tani A, Yoneda S, Shirahama H, Higashi M, et al. (1)(8)FDG PET for grading malignancy in thymic epithelial tumors: significant differences in (1)(8)FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study. Eur J Radiol. 2012;81:146\u201351.","journal-title":"Eur J Radiol"},{"key":"112_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/RLU.0000000000001032","volume":"41","author":"SY Park","year":"2016","unstructured":"Park SY, Cho A, Bae MK, Lee CY, Kim DJ, Chung KY. Value of 18F-FDG PET\/CT for Predicting the World Health Organization Malignant Grade of Thymic Epithelial Tumors: Focused in Volume-Dependent Parameters. Clin Nucl Med. 2016;41:15\u201320.","journal-title":"Clin Nucl Med"},{"key":"112_CR27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/JTO.0b013e3182835549","volume":"8","author":"MF Benveniste","year":"2013","unstructured":"Benveniste MF, Moran CA, Mawlawi O, Fox PS, Swisher SG, Munden RF, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;8:502\u201310.","journal-title":"J Thorac Oncol"},{"key":"112_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.lungcan.2011.02.018","volume":"74","author":"A Terzi","year":"2011","unstructured":"Terzi A, Bertolaccini L, Rizzardi G, Luzzi L, Bianchi A, Campione A, et al. Usefulness of 18-F FDG PET\/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer. 2011;74:239\u201343.","journal-title":"Lung Cancer"},{"key":"112_CR29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/icvts\/ivu068","volume":"19","author":"A Viti","year":"2014","unstructured":"Viti A, Terzi A, Bianchi A, Bertolaccini L. Is a positron emission tomography-computed tomography scan useful in the staging of thymic epithelial neoplasms? Interact Cardiovasc Thorac Surg. 2014;19:129\u201334.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"112_CR30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-12-2929","volume":"19","author":"A Thomas","year":"2013","unstructured":"Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman AW, et al. 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res. 2013;19:1487\u201393.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"112_CR31","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S\u201350S.","journal-title":"J Nucl Med"},{"key":"112_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra050276","volume":"354","author":"ME Juweid","year":"2006","unstructured":"Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496\u2013507.","journal-title":"N Engl J Med"},{"key":"112_CR33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12149-010-0455-x","volume":"25","author":"K Kaira","year":"2011","unstructured":"Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med. 2011;25:247\u201353.","journal-title":"Ann Nucl Med"},{"key":"112_CR34","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2009.27.4662","volume":"28","author":"K Kaira","year":"2010","unstructured":"Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746\u201353.","journal-title":"J Clin Oncol"},{"key":"112_CR35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","volume":"147","author":"RJ Korst","year":"2014","unstructured":"Korst RJ, Bezjak A, Blackmon S, Choi N, Fidias P, Liu G, et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg. 2014;147:36\u201344. 6 e1.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"112_CR36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","volume":"10","author":"HS Kim","year":"2015","unstructured":"Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, et al. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors. J Thorac Oncol. 2015;10:1800\u20136.","journal-title":"J Thorac Oncol"},{"key":"112_CR37","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1993.11.11.2101","volume":"11","author":"RL Wahl","year":"1993","unstructured":"Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101\u201311.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"112_CR38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00259-006-0133-3","volume":"33","author":"WA Weber","year":"2006","unstructured":"Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006;33 Suppl 1:27\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"112_CR39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnumed.107.045641","volume":"49","author":"R Fonti","year":"2008","unstructured":"Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, et al. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195\u2013200.","journal-title":"J Nucl Med"},{"key":"112_CR40","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/JTO.0000000000000289","volume":"9","author":"EM Marom","year":"2014","unstructured":"Marom EM, Detterbeck FC. Overview. J Thorac Oncol. 2014;9:S63\u20134.","journal-title":"J Thorac Oncol"},{"key":"112_CR41","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","volume":"9","author":"FC Detterbeck","year":"2014","unstructured":"Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, et al. The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S65\u201372.","journal-title":"J Thorac Oncol"},{"key":"112_CR42","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/JTO.0000000000000303","volume":"9","author":"AG Nicholson","year":"2014","unstructured":"Nicholson AG, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, et al. The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S73\u201380.","journal-title":"J Thorac Oncol"},{"key":"112_CR43","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1097\/JTO.0000000000000291","volume":"9","author":"K Kondo","year":"2014","unstructured":"Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, et al. The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S81\u20137.","journal-title":"J Thorac Oncol"},{"key":"112_CR44","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0000000000000296","volume":"9","author":"MF Benveniste","year":"2014","unstructured":"Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM, International Thymic Malignancy Interest G. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014;9:S119\u201324.","journal-title":"J Thorac Oncol"},{"key":"112_CR45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CCO.0b013e3282f5123d","volume":"20","author":"YL Kasamon","year":"2008","unstructured":"Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Curr Opin Oncol. 2008;20:206\u201319.","journal-title":"Curr Opin Oncol"},{"issue":"Suppl 1","key":"112_CR46","first-page":"19S","volume":"48","author":"YL Kasamon","year":"2007","unstructured":"Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET\/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007;48 Suppl 1:19S\u201327S.","journal-title":"J Nucl Med"},{"key":"112_CR47","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773\u201382.","journal-title":"Eur J Cancer"},{"key":"112_CR48","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626\u201332.","journal-title":"J Nucl Med"},{"key":"112_CR49","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1078-0432.CCR-07-0934","volume":"14","author":"K Ott","year":"2008","unstructured":"Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012\u20138.","journal-title":"Clin Cancer Res"},{"key":"112_CR50","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","volume":"23","author":"N Avril","year":"2005","unstructured":"Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445\u201353.","journal-title":"J Clin Oncol"},{"key":"112_CR51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.07.025","volume":"100","author":"SH Moon","year":"2016","unstructured":"Moon SH, Kim HS, Cho YS, Sun JM, Ahn JS, Park K, et al. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. Lung Cancer. 2016;100:24\u20139.","journal-title":"Lung Cancer"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-017-0112-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T12:01:10Z","timestamp":1498392070000},"score":1,"resource":{"primary":{"URL":"http:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-017-0112-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1186\/s40644-017-0112-x","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]},"article-number":"10"}}